CVS Health Corporation (NYSE:CVS) – Analysts at Jefferies Group boosted their FY2017 EPS estimates for CVS Health Corporation in a report released on Friday. Jefferies Group analyst B. Tanquilut now forecasts that the pharmacy operator will post earnings of $5.88 per share for the year, up from their previous estimate of $5.82. Jefferies Group has a “Hold” rating and a $86.00 price target on the stock. Jefferies Group also issued estimates for CVS Health Corporation’s Q4 2017 earnings at $1.90 EPS and FY2018 earnings at $6.34 EPS.

CVS Health Corporation (NYSE:CVS) last released its earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.02. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The business had revenue of $45.69 billion for the quarter, compared to analyst estimates of $45.36 billion. During the same quarter in the previous year, the company posted $1.32 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “FY2017 Earnings Estimate for CVS Health Corporation Issued By Jefferies Group (CVS)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/19/fy2017-earnings-estimate-for-cvs-health-corporation-issued-by-jefferies-group-cvs.html.

CVS has been the topic of a number of other reports. Vetr cut CVS Health Corporation from a “strong-buy” rating to a “buy” rating and set a $88.97 price target on the stock. in a research report on Monday, June 12th. Guggenheim reiterated a “buy” rating on shares of CVS Health Corporation in a research report on Monday, July 3rd. Needham & Company LLC reiterated a “hold” rating on shares of CVS Health Corporation in a research report on Sunday, September 10th. Citigroup Inc. dropped their price target on CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating on the stock in a research report on Thursday, August 17th. Finally, BidaskClub cut CVS Health Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $90.35.

Shares of CVS Health Corporation (NYSE CVS) opened at 83.31 on Monday. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $90.85. The stock has a market capitalization of $84.69 billion, a P/E ratio of 16.60 and a beta of 0.92. The company has a 50 day moving average price of $79.02 and a 200-day moving average price of $78.96.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. boosted its stake in shares of CVS Health Corporation by 0.6% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock worth $232,000 after acquiring an additional 18 shares in the last quarter. Keel Point LLC boosted its stake in shares of CVS Health Corporation by 0.7% during the 1st quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock worth $259,000 after acquiring an additional 22 shares in the last quarter. First City Capital Management Inc. boosted its stake in shares of CVS Health Corporation by 0.3% during the 1st quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock worth $1,003,000 after acquiring an additional 40 shares in the last quarter. Elefante Mark B boosted its stake in shares of CVS Health Corporation by 0.7% during the 2nd quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock worth $515,000 after acquiring an additional 45 shares in the last quarter. Finally, Traynor Capital Management Inc. boosted its stake in shares of CVS Health Corporation by 1.3% during the 2nd quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock worth $290,000 after acquiring an additional 48 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Helena Foulkes sold 20,333 shares of the firm’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $80.00, for a total transaction of $1,626,640.00. Following the completion of the sale, the executive vice president now directly owns 59,301 shares of the company’s stock, valued at approximately $4,744,080. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Larry J. Merlo sold 241,150 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $83.07, for a total value of $20,032,330.50. Following the sale, the insider now directly owns 299,255 shares of the company’s stock, valued at $24,859,112.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 591,328 shares of company stock valued at $47,927,439. 0.61% of the stock is currently owned by corporate insiders.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History and Estimates for CVS Health Corporation (NYSE:CVS)

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.